Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non-Current Assets (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non-Current Assets for 5 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets changed N/A to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.4 million for FY2025, N/A changed from the prior year.
  • Non-Current Assets for Q4 2025 was $2.4 million at Actinium Pharmaceuticals, up from $1.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $3.5 million in Q2 2023, with the low at $509000.0 in Q1 2022.
  • Average Non-Current Assets over 5 years is $2.4 million, with a median of $2.6 million recorded in 2024.
  • The sharpest move saw Non-Current Assets plummeted 62.3% in 2022, then surged 583.69% in 2023.
  • Over 5 years, Non-Current Assets stood at $639000.0 in 2021, then soared by 408.61% to $3.2 million in 2022, then decreased by 2.09% to $3.2 million in 2023, then dropped by 18.48% to $2.6 million in 2024, then fell by 7.71% to $2.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $2.4 million, $1.8 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.